eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2020
vol. 37
 
Share:
Share:
more
 
 
Review paper

The microbiome and its impact on food allergy and atopic dermatitis in children

Ewa Łoś-Rychalska
1
,
Marcin Gołębiewski
2, 3
,
Tomasz Grzybowski
4
,
Urszula Rogalla-Ładniak
4
,
Aneta Krogulska
1

1.
Department of Paediatrics, Allergology and Gastroenterology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
2.
Interdisciplinary Centre of Modern Technologies, Nicolaus Copernicus University, Torun, Poland
3.
Chair of Plant Physiology and Biotechnology, Nicolaus Copernicus University, Torun, Poland
4.
Chair of Forensic Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
Adv Dermatol Allergol 2020; XXXVII (5): 641-650
Online publish date: 2020/11/07
Article file
- The microbiome.pdf  [0.23 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 
The microbiome as a link between food allergy and atopic dermatitis

Although food allergy (FA) affects 4–10% of children [1], it is more frequently encountered in those with atopic dermatitis (AD), with around 15–30% of children with AD also being affected by FA [2]. AD is the most frequently observed chronic skin disease in children, affecting 15–20% of children worldwide, and is in turn more common in FA children than in the general population [1, 2]. The incidence of both FA and AD is growing [3]. Although a connection has long been recognized between the two diseases, the significance of FA in AD pathogenesis is still controversial. It has been shown that FA is connected with the exacerbation, persistence and earlier onset of AD [4], and that AD may precede FA [5]. Recent studies have shown that skin sensitization to food antigens has a significant influence on the occurrence of FA, suggesting a strong link between the skin and gut immune responses [6]. Some studies suggest that the skin and gut, which both constitute physical barriers, are linked via modulation of the immune environment via the microbiome [7, 8]. Currently, it is not clear whether modulation of the gut microbiome can impact upon the skin microbiome and vice versa. It is still not elucidated whether the skin and gut microbiomes cooperate together or can influence each other. Additionally, it is not known whether any microbiome pattern, common for skin and gut, exists and can determine sensitization to food and environmental allergens, or may predispose its host to develop an allergy. Certain studies report that during early infancy, the microbiome may determine both the development and clinical course of food allergy as well as tolerance to food allergens [9–11]. Analogically, changes in skin microbiome composition are observed in the course of AD. A decreased abundance of Staphylococci during early infancy may predict the onset of AD until the end of the first year of life, while an increase of microbiome diversity during the course of AD treatment might indicate a high probability of remission [12, 13]. Moreover, the composition of gut microbiota is closely correlated with the development of skin inflammation. The presence of Escherichia coli in stools is associated with a higher risk of developing eczema, while Clostridium difficile is related to increasing severity of AD [14]. Alterations in the gut microbiome may be associated with AD through the action of bacterial genes that can modulate host immune cell function [15].

The gut microbiome

Development of the gut microbiome

The infant gut microbiome is composed mainly (94–98%) of bacteria coming from four phyla: Firmicutes (~64%), Bacteroidetes (~23%), Actinobacteria (~3%) and Proteobacteria (~5%). Other phyla contribute small numbers of cells and their shares vary [9, 16]. The intestines of foetuses are sterile, and colonization begins at delivery [17, 18]; however, it has been suggested that in utero colonization may be possible [19]. The initial microbiomes develop during the first 6 weeks of life, evolving to reach stability at approximately the second or third year of life [20]. Later, only environmental factors may exert any significant impact on the composition of the intestinal microbiome [17]. The precise composition of microbial strains is characteristic of a given individual. Studies on twins with similar microbiomes suggest that the genetic makeup of the host may exert a strong influence on the microbiome [21]. It was established that genetically determined physiological features of human organism, such as metabolism or immunological system, influenced colonization. It seems, however, that this relation is reciprocal, i.e. the microbiome also influences these traits in humans. On the other hand, environmental factors, such as diet, lifestyle, family size, pet owning [22–24] or medical treatment (method of delivery, antibiotic therapy, probiotic therapy) are important for shaping the microbiome and its development (Table 1) [16, 18, 25–28]. Of special importance for the formation of the gut microbiome is breastfeeding (Table 1) [19, 29, 30]. Breast milk contains a diverse range of bacteria, some of which are derived from the skin [31]. The number of bacterial cells per millilitre is ~106 [32]. Bacteria belong to four phyla, with the Firmicutes predominating (with the Staphylococci being most common), followed by the Actinobacteria, Proteobacteria and Bacteroidetes [31, 33]. Maternal health, body mass, atopy, diet, immunological status, duration of pregnancy, method of delivery, antibiotic therapy and lactation phase are regarded as factors influencing the microbiome of breast milk [31–34]. Grönlund et al. report that a lower abundance of Bifidobacteria in milk coming from allergic mothers is connected with lower numbers of these bacteria in the stools of their children [34]. Moreover, the breast milk microbiome positively influences digestion and absorption as well as the maturation of the intestinal barrier and pathogen defence [31]. Additionally breastfeeding has a significant impact on the infant immune system, shifting the balance between Th1 and Th2 response towards Th1, thus decreasing predisposition to allergy [29].

The gut microbiome and food allergy

Food allergy can be driven by such factors as diet and commensal microbiota, and the interactions between them determine the default state of mucosal immune tolerance [35]. Not only is the gut microbiome less diverse in allergic patients, it also varies according to the declared allergy type [11]. Studies of the gut microbiota in patients with specific food allergies shows that it is plausible that distinct types of microbiota are associated with each FA subphenotype [35]. Fujimura et al. note the presence of compositionally-distinct neonatal human gut microbiota, whose compositions are differentially related to the relative risk of childhood atopy [36]. Given differences in the presentations and natural histories of specific food allergies, it is plausible that the microbiota associated with each food allergy subphenotype are also distinct. Infants allergic to peanuts have higher levels of Bacteroides [11], and those with cow’s milk allergy (CMA) have higher levels of anaerobic bacteria [37] Ruminococcaceae and Lachnospiraceae [38].
Following allergic sensitization, changes in microbial abundance and diversity (e.g. after antibiotic exposure) decrease SCFA, IL-18, and IL-22 levels, compromising epithelial integrity and thereby facilitating the epithelial passage of microbial and food antigens. DC activation promotes inflammation, allergic sensitization and the development of Th2 cell-associated immune responses, including the production of allergen-specific IgE antibodies [39]. There are hints indicating that disturbance in microbiome composition at early stages of development may influence the onset of sensitization and FA [8]. West et al. report that Bacteroidetes diversity was lower in the stools of pregnant women who delivered children who went on to develop IgE-mediated FA and AD [40]. Azad et al. demonstrated that the composition of gut microbiome at the third month of life can predict sensitization to food allergens until the twelfth month of life [10]. They found a greater abundance of Enterobacteriaceae and lower diversity of Bacteroidetes in the gut of children with allergy to at least one food allergen. Children typified by a higher Enterobacteriaceae/Bacteroidaceae ratio tended to have a greater risk of developing sensitization [10].
Chen et al. report that children with FA aged 6–24 months displayed decreased microbiome diversity, a lower number of species of Bacteroidetes and a greater number of species of Firmicutes compared with healthy children [9]. Ling et al. showed that children with FA display lower numbers of Bacteroidetes, Proteobacteria and Actinobacteria, but greater numbers of Firmicutes. Phylotypes characteristic of FA are negatively correlated with IL-10 concentration [41]. Children with IgE-mediated FA present more Anaerobacter and Clostridium sensu stricto, and less Bacteroides and Clostridium. Thus it was shown that microbiome differentiates children with FA from healthy ones; moreover, differences between IgE-mediated and non-IgE-mediated allergy were also visible [9, 40, 41].
West et al. demonstrate that Ruminococcaceae are less abundant at the first week and the first month of age in children that developed FA than in those who did not develop any allergy until the 30th month [40]. The number of species of these bacteria was negatively correlated with the concentration of IL-6 and TNF-a induced by TLR2. A negative correlation was also found between members of the Propionibacterium genus and TNF-a induced by TLR4. At 1 year of age, children with eczema demonstrated a lower diversity of Actinobacteria compared to healthy ones [40]. Simonyté Sjödin et al. report that between infancy and school age, the gut microbiota of children with IgE-associated allergic disease were different from those of healthy children and that these differences were related to T-cell regulation [42]. Ruminococcus, Bacteroides, Prevotella and Coprococcus were found to be underrepresented in children with allergy compared to those without throughout the period of examination. At 8 years old, the microbiome of allergic children was found to be rich in Bifidobacterium but depleted of Lactobacillus, Enterococcus and Lachnospira and Faecalibacterium, which was correlated with IL-10 mRNA and Foxp3 levels (forkhead box P3). Kourosh et al. describe differences in the intestinal microbiome between children with IgE-mediated FA, their siblings without FA and non-allergic controls [43].
Bunyavanich et al. demonstrated that the acquisition of tolerance by children with CMA is connected with a greater abundance of Clostridia and Firmicutes in general [44]. Berni Canani et al. report that such acquisition is associated with changes in microbiome composition and increased butyrate levels in stools [38].

Skin microbiome

Development of skin microbiome

A square centimetre of skin may harbour even a billion bacteria, fungi and viruses, and although the majority of these microorganisms belong to the same phyla present in the gut microbiome, they are found in different quantities: Actinobacteria (52–59%), Firmicutes (24%), Proteobacteria (17%) and Bacteroidetes (7%) [45, 46]. The predominant members are Propionibacterium, Streptococcus, Staphylococcus and Corynebacterium [46, 47]. The composition of the skin microbiome varies between individuals [48]. Its acquisition begins at birth [45, 49] with the transfer of the maternal microbiome [49]. The skin microbiome evolves over the years according to the changes of skin structure and functions, becoming similar to that of adults by the age of 12–18 months [46, 50, 51]. The composition of the skin microbiome is dependent on the host, age, gender and anatomical area [45, 48, 49, 52] as well as ethnicity, climate, lifestyle (contact with other individuals, visiting different places and diet) [47, 52, 53] and medical procedures (i.e. mode of delivery) (Table 2) [49].

Skin microbiome and atopic dermatitis

Presence of healthy skin microbiome results in signalling through IL-1R and inhibits Th2 immunological response [46]. Compared to healthy subjects, the skin microbiome of AD patients has been found to be less diverse and to be dominated by Staphylococcus aureus [54, 55]. Dysbiosis of skin microbiome also can contribute to food sensitization. In the skin, Staphylococcal enterotoxin B acts as an adjuvant to promote Th2 responses and T helper cell development while cytolysins lyse epithelial cells, and serine proteases and lipases damage the skin barrier [39]. Kennedy et al. report that in infants who later developed AD, the species richness of skin microbiome was decreased at the second month of life [12]. The important role played by the skin microbiome in AD pathogenesis was confirmed in a study by Laborel-Preneron et al., who report that the S. aureus thriving on inflamed skin in children sensitized to Dermatophagoides pteronyssinus promoted inflammation through Th2 activation and regulatory T cells (Tregs) suppression, and that commensal S. epidermidis may block this effect by influencing IL-10 release from skin dendritic cells [56]. Kong et al. [13] report an increased abundance of Staphylococcus, particularly S. aureus, in children with AD. Microbiome diversity increased during treatment, with a concomitant increase in the numbers of Streptococcus, Propionibacterium and Corynebacterium. Glatz et al. [57] demonstrated changes in skin microbiota, i.e. an increased proportion of S. salivarius, associated with long-term use of emollients, and confirmed its potential preventative measure in infants at risk for AD. There is increasing evidence that commensal skin microbes from normal skin can improve the skin barrier and augment host defence against skin pathogens, including S. aureus.

Influence of the gut and skin microbiome

on the immune system

The gut microbiome serves many functions to the host, but in allergy, the influence of the gut microbiome on the immune system is of key importance [21, 58]. It is thought that the most important function of the microbiome is its influence on the development and function of the immune system, maintaining the balance between the Th1/Th2 response, by regulating various lymphocyte subpopulations, especially Tregs, responsible for immune tolerance [11, 17, 21, 58–60]. In the absence of an intact intestinal microbiome, the levels of both IgE and circulating basophils are increased [61]. Cells, cytokines, receptors involved in the regulation of type 2 immune response via the microbiome are illustrated in Figure 1. The microbiome employs various mechanisms to influence the immune system, including direct reception and modifications at the epigenetic level (DNA methylation, histone acetylation and micro RNA activities) [21, 62, 63]. The differences in early gut microbiome composition that might exist between allergic and non-allergic subjects could be a part of causes of epigenetic modification through SCFAs, particularly butyrates as well as by vitamins of the B group and other methyl group donors that are metabolized by gut microbiome [64–67]. Microbes can modulate immunologic functions related to allergic diseases also through small molecules produced during metabolism [39, 68–70] as well as through their cell envelope or capsular components (such as DNA, RNA, proteins and cell wall components) (Table 3).Diverse microbial metabolites profoundly regulate the immune system via host receptors and other target molecules [68, 70–74]. It has been found that commensal bacteria, especially lactic acid bacteria generate metabolites which decrease the levels of inflammatory cytokines, induce the production of anti-inflammatory cytokines and enhance the epithelial barrier function [69, 75].
Short-chain fatty acids (SCFAs), as the most abundant microbial metabolites of the colonic lumen, play a wide range of regulatory roles in the immune system, including mediating the induction of immune tolerance and proliferation of Tregs [21, 62] (Figure 2). SCFAs act as the main energy source of epithelial cells and influence the expression of genes necessary for maintaining the epithelial barrier and defence functions. They regulate the action of innate immune cells such as macrophages, neutrophils, dendritic cells, and bidirectionally regulate antigen-specific adaptive immunity mediated by T cells and B cells. It has been indicated that amino acids may also have a potential influence on the development, homeostasis and function of immune cells. Oral treatment with poly-g-glutamic acid (g-PGA) decreases the levels of serum immunoglobulin E (IgE) and Th2 cytokines, resulting in the attenuation of the clinical symptoms of AD by influencing the Th1/Th2 balance [76]. Indoxyl 3-sulfate, a derivative of indole produced from tryptophan by Lactobacillus rhamnosus GG and Lactobacillus casei W56 have the potential to enhance Treg cell induction [69]. Some commensal bacteria have the capacity to synthesize essential vitamins, especially B-family members, which have been reported to demonstrate some immunologic functions [38].
In addition to its immunologic effects, the microbiome may also influence susceptibility to FA through other mechanisms, including the control of intestinal barrier function. For example, microbe-induced IL-22 production by RORgt+ innate lymphocytes and CD4+ T cells promotes barrier integrity and intestinal epithelial cell synthesis of antimicrobial peptides and mucus [39]. Stefka et al. demonstrated that colonization with Clostridia spp. increased the expression of IL-22, a barrier-promoting cytokine, and decreased intestinal permeability [7]. The skin microbiome has been shown to promote normal skin homeostasis, maintaining skin barrier integrity and pathogen defence [46]. It works through the induction of the Th17 and T helper cell immune response and secretion of antimicrobial peptides (AMPs) [52]. It activates and assists innate immunity, and influences adaptive immunity, although these complex interactions are not completely understood. It is needed for the development of a well-functioning immune system and the modulation of the inflammatory processes [48, 52, 77, 78]. Figure 3 summarizes the relationships between the microbiome and skin and gut barriers. Some of commensals are capable to produce bacteriocins to inhibit the growth of harmful bacteria and to produce preventive biofilm [46].

The microbiome and probiotic therapy

A number of studies have evaluated the possibility of modifying the gut microbiome, particularly with regard to the influence of the microbiome on the risk and course of allergy. Some studies suggest that probiotic therapy may be an alternative to dietary treatment in CMA. Tolerance-promoting methylation changes were more frequently observed in patients receiving Lactobacillus GG [64, 79]. Martin et al. describe four cases of breastfed infants with allergic proctocolitis where LGG (L. rhamnosus GG) treatment, used without restrictions in the maternal diet, resulted in remission [80]. Cox et al. found that the use of LGG supplementation was associated with changes in the gut microbiome, with a lower abundance of species known to be involved in the observed pathogenesis of atopy [81].
According to Francavilla et al., the addition of lactose to an extensively hydrolysed formula positively modulated the microbiome composition, promoting the growth of bacteria observed in healthy children [82]. A previous study found that Lactobacillus probiotics are useful for the prevention, rather than treatment of AD [83]. Recently, Lactobacillus plantarum was also found to reduce the clinical index in children with AD, and this effect was associated with an increase in Treg population [84–88]. Only a few trials evaluating the use of probiotics for the prevention or treatment of challenge-proved food allergies have been published. Trials of probiotic supplementation with Lactobacillus casei and Bifidobacterium lactis for 12 months showed no effect on milk allergy resolution, although Lactobacillus rhamnosus combined with extensively hydrolysed casein formula increased rates of milk allergy resolution compared with a control group receiving formula alone [89, 90]. The probiotic Lactobacillus rhamnosus GG administered with peanut oral immunotherapy for 18 months induced desensitization compared with placebo [91]. The effects of probiotic treatment are likely strain specific, and the findings are currently insufficient to support probiotic supplementation with specific taxa for FA treatment.
A novel therapeutic strategies aimed to restore natural skin microbiome, for example application of probiotic strains/topical microbiome transplantation are being studied [46].

Conclusions

Changes in the microbiome confer protection or susceptibility to FA or AD by modulating the immune system. The potential role of exposure to microbes during early childhood in the development of FA as well as AD, and the subsequent atopic march remains to be elucidated. Early childhood appears to be critical for the colonization of a diverse microbiome. Recent research efforts have focused on the identification of bacterial strains necessary for oral tolerance and identification of the most effective probiotic strains for the prevention and treatment of FA. The role of skin microbiome in the course of FA and acquiring tolerance to food allergens by children is still unknown. Early skin topical treatment could reduce S. aureus colonization through exerting an anti-inflammatory effect. The management of skin diseases in the future may include manipulation of the gut function. Balancing the gut and skin microbiome will likely represent an effective treatment for allergy. Therefore, extensive studies are required to identify the interactions between the gut and skin microbiomes.

Acknowledgments

Project financed by National Science Centre, Poland, ul. Królewska 57, 30-081, Kraków, Grant number: 2017/25/B/NZ5/00141.

Conflict of interest

The authors declare no conflict of interest.
Copyright: © 2020 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe